Income Stocks With Improving Earnings Outlooks

Conviction: 72% · Horizon: 1Y · 2026-08-13
Rising earnings estimates and above-industry dividend yields support income-focused upside.

JPMorgan Chase and Microchip Technology combine improving current-year earnings expectations with dividend yields that exceed their respective industry averages.

Instrument Side Target Reason
WMG Long Warner Music Group benefits from an 8.6% increase in current-year earnings expectations over the last 60 days and offers a 2.5% dividend yield, well above the industry average of 0.7%.
ROK Long Current-year earnings estimates have risen 6.9% over the last 60 days, while the company offers a 1.1% dividend yield versus a 0.0% cited industry average.
NXRT Long Current-year earnings expectations have risen 9.3% over the last 60 days, while the REIT offers an 8.6% dividend yield that is well above the industry average.
CMI Long Current-year earnings estimates have increased 12.6% over the last 60 days, and the 1.1% dividend yield stands above the cited 0.6% industry average.
ADI Long Current-year earnings estimates have climbed 11.6% over the last 60 days, supported by a 1.1% dividend yield versus a 0.0% cited industry average.
JPM Long JPMorgan Chase offers a stronger-than-industry dividend yield while current-year earnings expectations have risen meaningfully, suggesting improving fundamentals alongside income appeal.
MCHP Long Microchip Technology combines rising current-year earnings expectations with a dividend yield well above its industry average, supporting a long thesis for investors seeking income and improving fundamentals.
QUAD Long Earnings expectations for the current year have improved 5.8% over the last 60 days, and the company offers a 3.9% dividend yield versus no yield for the industry average.
MSBI Long Current-year earnings expectations have increased 7.3% over the last 60 days, and the bank holding company provides a 3.7% dividend yield above the 2.2% industry average.

Themes

COIN CRCL Stablecoins 2026-08-12
ABCL AI Drug Discovery 2026-08-12

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.